Premium
Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
Author(s) -
Ye B. S.,
Lee W. W.,
Ham J. H.,
Lee J. J.,
Lee P. H.,
Sohn Y. H.
Publication year - 2016
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.12969
Subject(s) - uric acid , medicine , biomarker , confounding , cognitive decline , dementia , mini–mental state examination , cerebrospinal fluid , endocrinology , cognition , alzheimer's disease , cognitive test , gastroenterology , disease , psychiatry , biochemistry , biology
Background and purpose The association of serum uric acid, cerebrospinal fluid ( CSF ) biomarkers of Alzheimer's disease ( AD ) and longitudinal cognitive decline was evaluated using the AD Neuroimaging Initiative database. Methods In 271 healthy subjects, 596 mild cognitive impairment patients and 197 AD patients, serum uric acid and CSF AD biomarkers were measured at baseline, and Mini‐Mental State Examination and AD Assessment Scale − Cognitive Subscale ( ADAS ‐cog) were assessed serially (mean duration, 2.9 years). The effect of uric acid on longitudinal cognitive decline was evaluated using linear mixed effect models for Mini‐Mental State Examination and ADAS ‐cog scores in female and male subjects separately, with possible confounders controlled (model 1). To determine the effects of uric acid independent of CSF biomarker (Aβ 1–42 or tau) and to test whether the detrimental effects of CSF biomarker differ according to uric acid, CSF biomarker and its interaction with uric acid were further included in model 1 (model 2). Results Higher levels of uric acid were associated with slower cognitive decline, particularly in the mild cognitive impairment and dementia subgroups, and more prominently in female subjects. Model 2 with CSF Aβ 1–42 showed that higher levels of uric acid were associated with a slower cognitive decline and alleviated the detrimental effect of Aβ 1–42 on cognitive decline. Model 2 with CSF tau showed that higher levels of uric acid alleviated the detrimental effect of tau on cognitive decline in female subjects but not in male subjects. Conclusion Higher levels of uric acid had protective effects on longitudinal cognitive decline independent of and interactively with CSF AD biomarkers.